Latest 10-K annual reports

Alpha Star Acquisition Corporation reports a significant working capital deficit and going concern doubt as its merger with OU XDATA GROUP remains unconsummated and it navigates post-Nasdaq delisting challenges.

ENB Financial Corp achieved record net income and strong profitability growth in 2025, driven by increased net interest income and a strategic acquisition.

Security Federal Corporation reported a significant increase in net income available to common shareholders for 2025, driven by higher net interest income and a reversal of credit losses, despite a decrease in overall loan balances.

Oculus Inc. reported continued substantial losses and zero revenue for fiscal year 2025, raising significant doubts about its ability to continue as a going concern without substantial new financing.

Union Bankshares, Inc. reported a significant increase in net income for 2025, driven by higher net interest income and strategic balance sheet repositioning, despite a challenging interest rate environment.

Leapfrog Acquisition Corporation's 10-K filing outlines its blank check company structure, investment strategy in energy and infrastructure, and significant risks associated with SPACs.

Starwood Real Estate Income Trust, Inc. reported a GAAP net loss of $691.6 million for 2025, with share repurchase requests consistently exceeding monthly and quarterly limits.

Skyline Bankshares, Inc. reported a significant increase in net income for 2025, driven by robust loan portfolio growth and an improved net interest margin, following its 2024 acquisition of Johnson County Bank.

First Seacoast Bancorp reported an increased net loss for fiscal year 2025, alongside a rise in non-performing loans and a breach of interest rate risk policy limits.

Victoria's Secret & Co. reported a 5% increase in net sales to $6.553 billion for fiscal year 2025, but operating income declined to $271 million due to significant non-recurring charges, while advancing its 'Path to Potential' growth strategy.

Milestone Pharmaceuticals Inc. announced FDA approval for its first commercial product, CARDAMYST nasal spray for PSVT, and is advancing etripamil for AFib-RVR while expanding international regulatory efforts.

Dollar General reported a significant rebound in fiscal year 2025 with a 5.2% increase in net sales and a 34.4% rise in net income, driven by higher same-store sales and strategic initiatives.

Aeva Technologies, a 4D LiDAR pioneer, announced a significant 99% revenue increase to $18.1 million in 2025, alongside continued net losses and strategic partnerships.

Odysight.ai Inc. reported a 24% revenue decline and a 45% increase in net loss for 2025, driven by a strategic pivot from medical devices to vision-based AI solutions for predictive maintenance.

SilverBox Corp IV, a SPAC, reported its annual results for 2025, highlighting a net income of $5.7 million and progress on its proposed business combination with Parataxis Holdings Inc.

Strawberry Fields REIT, Inc. reported significant revenue and net income growth in 2025, driven by strategic acquisitions and increased rental income, despite rising interest and operating expenses.

Strive, Inc. significantly expanded its bitcoin holdings to 13,628 by March 2026, driven by strategic acquisitions and purchases, despite reporting a substantial net loss of $393.6 million for fiscal year 2025.

Spire Global reported a net income of $51.3 million for 2025, primarily driven by the $238.9 million sale of its maritime business, despite a 35% revenue decline and ongoing material weaknesses in internal controls.

Eledon Pharmaceuticals' 2025 annual report details promising clinical trial results for tegoprubart in kidney and islet cell transplantation, alongside ongoing financial losses and the need for additional capital.

Columbus Acquisition Corp (CAC) is progressing with its business combination with WISeSat.Space Holdings Corp. (Pubco) and WISeSat.Space Corp. (Target), despite significant shareholder redemptions and ongoing going concern considerations.

Bakkt, Inc. reported a significant decline in revenue and increased net losses for fiscal year 2025, driven by client departures, despite completing a strategic transformation to focus on digital asset infrastructure and securing new capital.

Avalon Holdings Corporation reported a net loss in 2025, driven by decreased golf and related operations revenue and ongoing legal expenses, despite improved working capital.

NovaBay Pharmaceuticals, Inc. has completed a significant business realignment, divesting its legacy pharmaceutical operations to focus on a blockchain-based digital asset strategy, primarily acquiring SKY tokens.

Netlist grew 2025 revenue 28% on AI-driven demand but recorded a net loss, extended its credit facility, raised equity, and flagged key risks including SK hynix supply expiry and ongoing IP litigation.

Coeptis Therapeutics Holdings, Inc. reports a net loss of $12.28 million for 2025, driven by increased operating expenses, while strategically expanding its technology segment and pursuing a merger and spin-out of its biotech operations.

Intuitive Machines, Inc. reported a reduced net loss in 2025, driven by strategic acquisitions and significant capital raises, as it advances its 'Build-Connect-Operate' space infrastructure strategy.

MultiSensor AI Holdings, Inc. reported a net loss of $11.7 million for 2025, a significant improvement from the prior year, while increasing active sensors on its MSAI Connect platform by 59%.

Red Cat Holdings, a U.S.-based drone and robotic solutions provider, reported significant revenue growth in 2025 driven by U.S. Army drone deliveries, alongside substantial capital raises, despite continued net losses.

BullFrog AI Holdings, Inc. reported a net loss of $6.5 million for 2025 and faces potential delisting from Nasdaq due to non-compliance with equity and minimum bid price requirements, despite initial revenue generation and strategic collaborations.

Harvard Apparatus Regenerative Technology, Inc. reports a significant accumulated deficit and auditor's going concern qualification, alongside delays in patient recruitment for its pivotal esophageal regeneration clinical trial, despite revenue growth in its consumer health segment.